Following Pharmac’s announcement that it will fund subcutaneous ocrelizumab for people with multiple sclerosis, MSNZ Vice-President and MS Taranaki President Graham Walker appeared on Breakfast TV to discuss what this decision means for him and the MS community.
During the segment, the Medical Director of Roche New Zealand highlighted a key system benefit of the new treatment option, noting that “20,000 hours of infusion time would be saved” by shifting patients from IV infusions to the subcutaneous version.
Watch the Breakfast tv interview: